top of page

Seattle based Umoja Biopharma is a pioneer of in vivo CAR-T cell engineering. CEO Andrew Scharenberg describes the technical innovations they have come up with to help make it succeed

  • Dec 11, 2024
  • 1 min read

He describes Umoja's numerous platforms that are aimed at maximizing in vivo success, including the company's proprietary lentiviral vector, a rapamycin based architecture to help the CAR-T cells expand and survive, and a tumor tagging technology that may help in tricky solid tumor settings. Umoja is the first company to have an IND cleared for an in vivo program in the United States.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page